USFDA inspects Zydus Lifesciences Ahmedabad SEZ facility
The company will address the observations within a stipulated timeline working with the regulators
The company will address the observations within a stipulated timeline working with the regulators
This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
The RRA was conducted from 22nd August, 2022 to 26th August, 2022.
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
Subscribe To Our Newsletter & Stay Updated